• Home
  • Study Details
By physician referral or invitation only

Drug Induced Liver Injury Study

Liver injury due to prescription and non-prescription medication is medical, scientific, and public health problem of increasing frequency and importance in United States. Drug-induced liver injury (DILI) is the most common reason the Food and Drug Administration (FDA) would choose not to approve a new drug or withdraw a drug from the market. However, drug-induced liver injuries are often under-reported and difficult to detect/diagnose. This study seeks to learn more about these drug-induced liver injuries and develop better ways to detect, define, and study drug-induced liver injuries. The study will be looking at new cases of drug-induced liver injury, as well as gathering data on previous drug-induced liver injury (up to January 1, 1994).

Age & Gender

  • 2 years ~ 99 years
  • Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is recruiting by invitation only.

United States (Nationwide)

Additional Study Information

Principal Investigator

Paul Watkins
UNC Eshelman School of Pharmacy-Division of Pharmacotherapy and Experimental Therapeutics

Study Type

Clinical or Medical
Observational

Study Topics

Injury/Injury Prevention
Kidneys and Liver

IRB Number

23-3281

Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research